Quantcast

Latest West syndrome Stories

2011-02-16 05:30:00

ANAHEIM, Calif., Feb. 16, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that Standard & Poor's (S&P) will add the Company to the S&P SmallCap 600 Index effective after the close of the U.S. financial markets on February 17, 2011. "Our inclusion in the S&P SmallCap 600 Index reflects our consistent financial performance, and will serve to increase our visibility within the investment community as we continue our efforts to grow sales...

2010-11-03 05:01:00

UNION CITY, Calif., Nov. 3, 2010 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that the commercial launch is now underway for H.P. Acthar® Gel (repository corticotropin injection) as monotherapy for the treatment of Infantile Spasms (IS) in infants and children under the age of two years. This new Acthar indication was approved by the U.S. Food and Drug Administration (FDA) on October 15, 2010. Acthar provides an important treatment...

2010-10-15 08:29:00

ANAHEIM, Calif., Oct. 15 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced the U.S. Food and Drug Administration (FDA) has approved Questcor's supplemental new drug application (sNDA) for H.P. Acthar® Gel (repository corticotropin injection) in the treatment of infantile spasms (IS), an ultra-rare orphan disorder affecting approximately 2,000 American children annually. IS is a devastating and potentially life-threatening form of...

2010-10-14 08:01:00

UNION CITY, Calif., Oct. 14 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) announced that it is partnering with the Child Neurology Foundation (CNF) to fund a $30,000 grant to support research into infantile spasms (IS). Catherine Chu-Shore, MD, of Massachusetts General Hospital was selected by CNF as the recipient of this first-ever "Logan Infantile Spasms Research Award." "Questcor is committed to CNF and the entire infantile spasms community," said Steve Cartt, Executive...

2010-10-13 11:39:00

MINNEAPOLIS, Oct. 13 /PRNewswire/ -- The Child Neurology Foundation (CNF) announced today the start of Infantile Spasms Awareness Week, an annual event to raise awareness and understanding of infantile spasms (IS) with pediatricians, child neurologists, parents and caregivers. Over the past year, CNF has developed a website, www.infantilespasmsinfo.org, that provides information on IS from leading child neurologists and shares stories from families coping with this devastating condition....

2010-10-11 08:01:00

UNION CITY, Calif., Oct. 11 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it is partnering with the Child Neurology Foundation (CNF) in support of the 2nd annual Infantile Spasms (IS) Awareness Week, which will take place October 11-17, 2010, in conjunction with the Child Neurology Society (CNS) Annual Meeting in Providence, Rhode Island. Over the past year, CNF has developed a website, www.infantilespasmsinfo.org, that provides information on IS...

2010-05-17 15:01:43

The high-fat ketogenic diet can dramatically reduce or completely eliminate debilitating seizures in most children with infantile spasms, whose seizures persist despite medication, according to a Johns Hopkins Children's Center study published online April 30 in the journal Epilepsia. Infantile spasms, also called West syndrome, is a stubborn form of epilepsy that often does not get better with antiseizure drugs. Because poorly controlled infantile spasms may cause brain damage, the Hopkins...

2010-02-25 07:03:00

CORAL GABLES, Fla., Feb. 25 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced that it will be making a presentation today at the 2010 Epilepsy Pipeline Update Conference, an in-depth, two day forum being held at the Hyatt Embarcadero Hotel in San Francisco. For additional program information, please visit www.epilepsy.com/node/985708. As previously reported, the Company will present an overview of CPP-115, Catalyst's development stage...

2010-02-22 07:03:00

CORAL GABLES, Fla., Feb. 22 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) will hold a conference call on Tuesday, February 23, 2010 to discuss its initial development plans for CPP-115. Patrick J. McEnany, Catalyst Pharmaceutical's Chief Executive Officer, will host the call. CPP-115 is a compound in a new class of GABA aminotransferase inhibitors in-licensed by Catalyst from Northwestern University. Catalyst is seeking to develop new prescription...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related